期刊
TRENDS IN CANCER
卷 5, 期 6, 页码 365-390出版社
CELL PRESS
DOI: 10.1016/j.trecan.2019.04.004
关键词
-
类别
资金
- Israel Science Foundation (ISF) [700/16]
- Israel Cancer Association (ICA) [20170024]
- Israel Cancer Research Foundation (ICRF) [17-1693-RCDA]
- United States-Israel Binational Science Foundation (BSF) [2017323]
- Concern Foundation [7895]
- LYriCAN [INCa-DGOS-Inserm_12563]
- Alon fellowship
- BGU Kreitman fellowships
Most Phase II and III clinical trials in head and neck cancer (HNC) combine two or more treatment modalities, which are based, in part, on knowledge of the molecular mechanisms of innate and acquired resistance to monotherapy. In this review, we describe the range of tumor-cell autonomously derived (intrinsic) and tumor-microenvironment-derived (extrinsic) acquired-resistance mechanisms to various FDA-approved monotherapies for HNC. Specifically, we describe how tumor cells and the tumor microenvironment (TME) respond to radiation, chemotherapy, targeted therapy (cetuximab), and immunotherapies [programmed cell death 1 (PD-1) inhibitors] and adapt to the selective pressure of these monotherapies. Due to the diversity of adaptive responses to monotherapy, monitoring the response to treatment in patients is critical to understand the path that leads to resistance and to guide the optimal therapeutic drug combinations in the clinical setting. We envisage that applying such a rationale-based therapeutic strategy will improve treatment efficacy in HNC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据